# Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

> **NCT00918281** · PHASE2 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 70 (actual)

## Conditions studied

- Solid Tumors
- High Grade Gliomas
- Lung Cancer
- Head and Neck Cancer
- Sarcoma
- Renal Cell Carcinoma
- Breast Cancer

## Interventions

- **DRUG:** Fluciclatide Injection

## Key facts

- **NCT ID:** NCT00918281
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-09
- **Final completion:** 2011-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2014-06-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918281, "Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00918281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*